Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2025-12-01

Summary

This study is a multicenter, open, non-randomized phase II clinical trial consisting of a safety introduction phase followed by a single-arm phase 2 phase. This phase II trial enrolled patients with HR+/HER2- advanced breast cancer who had failed aromatase inhibitor (AI)/fulvestrant CDK4/6i. Pts failing prior AI CDK4/6i received nab-Sirolimus + fulvestrant, while those failing fulvestrant CDK4/6i received nab-Sirolimus + AI.

• Phase: PHASE2

Details

• Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Treatments: Anastrozole; exemestane; Fulvestrant; Injections; Letrozole; Sirolimus